The Drug Enforcement Administration (DEA) has been sued over a failure to respond in due time to requests for psychedelics and cannabis records, reported Marijuana Moment.
This new suit centers on the DEA’s alleged “unlawful policy of delaying responses to Freedom of Information Act (FOIA) requests, specifically pertaining to psychedelics and marijuana documents that advocates say they’ve sought for legal and journalistic purposes."
DEA “flouts these principles of transparency and good government,” reads the lawsuit. Attorney General Merrick Garland issued a Justice Department FOIA guidance on policy, emphasizing that "agencies should be responsive to requests in an open and timely manner."
Among the sues, a Texas doctor cited in Texas federal district court the erroneous DEA’s interpretation of “right to try” laws as it concerns psilocybin. Attorneys Matt Zorn and Kathryn Tuckerboth worked on that case as well.
Plaintiffs have laid out the reasons why they are impacted by DEA’s refractoriness on FOIA requests, "the agency has adopted an unlawful policy and pattern or practice of designating requests as “complex,” regardless of the actual complexity of the documents sought," reads the lawsuit.
For its part, the DEA has said that the requests raise “unusual circumstances” that exempt them from the statutorily imposed timeline for responding. Also, the DEA defense says that "assigning the FOIA inquiries is “complex” because retrieving the documents in question might involve coordinating with outside offices."
“This policy and pattern or practice rest on a perversion of FOIA’s plain language,” stated the suit. “Plaintiffs are attorneys and their clients who have submitted FOIA requests to DEA only to have the agency unlawfully ignore the statute’s processing deadlines merely because the requested records were not present at DEA’s FOIA office.”
Now, the plaintiffs are asking the court to enjoin the Justice Department and DEA “from applying the unlawful policy and pattern or practice and directing defendants to take immediate corrective action to prevent future FOIA violations.”
Image by Benzinga
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.